Recent Research Analysts’ Ratings Changes for Erasca (ERAS)

Several analysts have recently updated their ratings and price targets for Erasca (NASDAQ: ERAS):

• 1/13/2026 – Erasca had its price target raised by analysts at HC Wainwright from $6.00 to $11.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Erasca was given a new $10.00 price target on by analysts at Stifel Nicolaus.
• 1/8/2026 – Erasca was given a new $4.00 price target on by analysts at Morgan Stanley.
• 1/7/2026 – Erasca is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $5.00 price target on the stock.
• 1/7/2026 – Erasca is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $5.00 price target on the stock.
• 12/9/2025 – Erasca had its price target raised by analysts at Mizuho from $4.00 to $5.00. They now have an “outperform” rating on the stock.
• 11/14/2025 – Erasca had its price target raised by analysts at Guggenheim from $3.00 to $5.00. They now have a “buy” rating on the stock.

Insider Activity at Erasca

In related news, General Counsel Ebun Garner sold 120,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $5.59, for a total value of $670,800.00. Following the sale, the general counsel owned 25,076 shares of the company’s stock, valued at $140,174.84. The trade was a 82.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 14.40% of the company’s stock.

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.